About US
Neurodyn's goal is to be a first in-class biopharmaceutical company discovering and developing novel cures for neurological diseases. Leveraging a powerful molecule providing broad neuroprotective benefits in vitro and in vivo, we believe that we are well on our way to achieving our goal with ND-602 and a diagnostic ND-803.
We believe that our candidate therapeutics have the potential to change the paradigm of how some neurological diseases are treated, not only providing patients with new cures, but also hope for a better quality of life.
ND-602
ND-602 is a patent pending therapeutic that provides unprecedented protection for neurons from damage that can lead to dysfunction and ultimately neuronal death. That is why we believe ND-602 has the potential to become a first-in-class disease-modifying intervention for PD. In a proprietary, slowly progressive Parkinson's disease animal model, ND-602 protects dopamine-releasing neurons from a host of environmental damage. Similarly, ND-602 affords essentially complete protection against the industry standard acute models of Parkinson's disease. These results support our hypothesis that ND-602 could be the potential next-generation treatment that goes beyond dopamine replacement.Because of the generalized neuroprotective effect of ND-602 we have extended our in vivo studies to Alzheimer's disease, ALS and Spinal Muscular Atrophy. While positive results for all indications, most spectacular were the Alzheimer's results.
Using the Tg2576 model, ND-602 was able to significantly reduce beta amalyoid plaques. Most surprising, however was survival. Typically about 1/3 of the, Tg2576 animals die between 8 and 12 months of age. This happened with the control animals and the mock treated animals. However, 95% of the ND-602 animals were still alive and healthy at the conclusion of the study.
Enhanced Natural Ginseng
Utilizing a slowly progressive model of Parkinson's disease (see CNS CRO for details), a novel extract of ginseng was shown to provide near complete protection of nigral dopaminergic neurons and striatal innervation. This confirms earlier work demonstrating the potential of this extract as a neuroprotective therapy for Parkinson's disease and introduces a novel model for screening neuroprotective candidates.
Many neuroprotective candidates have shown great promise in rodent models only to then fail in the clinic. This may be due in large part to the inadequacy of current acute or "end stage" rodent models, which fail to mimic the progressive nature of the disease. CNS CRO offers a suite of models to address this short coming.